Document is current
Any future updates will be listed below
-
Authors
Malcikova, Jitka https://orcid.org/0000-0003-3650-6698
Pavlova, Sarka https://orcid.org/0000-0003-1528-9743
Baliakas, Panagiotis https://orcid.org/0000-0002-5634-7156
Chatzikonstantinou, Thomas https://orcid.org/0000-0003-4105-1253
Tausch, Eugen
Catherwood, Mark
Rossi, Davide
Soussi, Thierry https://orcid.org/0000-0001-8184-3293
Tichy, Boris
Kater, Arnon P. https://orcid.org/0000-0003-3190-1891
Niemann, Carsten U. https://orcid.org/0000-0001-9880-5242
Davi, Frederic
Gaidano, Gianluca https://orcid.org/0000-0002-4681-0151
Stilgenbauer, Stephan https://orcid.org/0000-0002-6830-9296
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
Stamatopoulos, Kostas https://orcid.org/0000-0001-8529-640X
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Pospisilova, Sarka https://orcid.org/0000-0001-7136-2680
- License Information
-
More Information
Article History
Received: 4 January 2024
Revised: 24 April 2024
Accepted: 25 April 2024
First Online: 16 May 2024
Competing interests
: SPav has received honoraria from AstraZeneca. PB has received honoraria from Abbvie, Gilead and Janssen, and research funding from Gilead. ET has received honoraria from Abbvie, AstraZeneca, BeiGene, Janssen and Hoffmann-La Roche, and research support from Abbvie, Roche and Gilead. DR has received honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Janssen and Lilly, research grants from AbbVie, AstraZeneca and Janssen, and travel grants from AstraZeneca and Janssen. AK has received research funding from BMS, Astra Zeneca, Janssen, Abbvie and Roche Genentech, and compensation as a member of the scientific advisory board from BMS, Astra Zeneca, Janssen, Abbvie, Roche Genentec and LAVA. CUN has received research funding and/or consultancy fees from Abbvie, AstraZeneca, Beigene, Janssen, Genmab, Lilly, MSD, CSL Behring, Takeda and Octapharma. FD has received honoraria from Janssen and AstraZeneca. GG has received compensation as a member of the scientific advisory board from Abbvie, Astra Zeneca, BeiGene, Incyte, Janssen and Lilly, and Speaker’s Bureau honoraria from Abbvie, BeiGene, Astra Zeneca and Janssen. SS has received compensation as a member of the scientific advisory board, research support, travel support and speaker fees from AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann-La Roche, Infinity, Janssen, Lilly, Novartis, Sunesis, and Verastem. RR has received honoraria from AbbVie, AstraZeneca, Janssen, Illumina, and Roche. KS has received research funding, honoraria and/or consultancy fees from Abbvie, AstraZeneca, Janssen, Lilly and Roche. PG has received honoraria from AbbVie, Astrazeneca, BeiGene, BMS, Galapagos, Janssen, Lilly/Loxo Oncology, MSD and Roche, and research funding from AbbVie, Astrazeneca, BMS and Janssen.
